What is INBX stock price today?

INBX (Inhibrx Biosciences Inc) stock is trading at $83.07 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is INBX stock going up or down today?

INBX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy INBX stock now?

The decision to buy INBX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is INBX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for INBX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is INBX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if INBX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is INBX's P/E ratio?

P/E ratio data for INBX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is INBX's market cap?

INBX (Inhibrx Biosciences Inc) has a market capitalization of $1.22 billion, making it a small-cap stock.

What is INBX's price to book ratio?

INBX trades at a price-to-book (P/B) ratio of 152.03, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does INBX pay dividends?

INBX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is INBX's dividend yield?

INBX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is INBX stock a good long-term investment?

INBX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is INBX's revenue growth rate?

INBX has shown revenue growth of -1.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for INBX are available on our dashboard with complete income statement analysis.

What are the risks of investing in INBX?

Key risks for INBX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does INBX compare to its competitors?

Compare INBX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize INBX's performance and positioning.

What is INBX's stock price target for 2026?

Our AI model provides price targets for INBX based on fundamental analysis: Bull case $107.99 (+30%), Base case $95.53 (+15%), Bear case $74.76 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about INBX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for INBX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is INBX's next earnings report?

INBX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

INBX - Inhibrx Biosciences Inc

NYSE * Health Care * Biotechnology

$83.07

$-0.12 (-0.14%)

About Inhibrx Biosciences Inc

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

INBX Key Statistics

Market Cap

$1.22B

P/B Ratio

152.03

EPS

$-9.04

Revenue Growth

-1.0%

Employees

109

How INBX Compares to Peers

INBX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
INBX(This stock)	$1.22B	N/A	-1%	0.0%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Inhibrx Biosciences Inc Company Information

Headquarters: California; U.S.A
Website: inhibrx.com
Sector: Health Care
Industry: Biotechnology

INBX - Inhibrx Biosciences Inc

About Inhibrx Biosciences Inc

INBX Key Statistics

How INBX Compares to Peers

Inhibrx Biosciences Inc Company Information

INBX Lician Score

INBX Financial Snowflake

Upcoming Events for INBX